U.K.'s NICE Clears Lucentis For Treating Diabetic Macular Edema The U.K.'s cost-effectiveness agency gave a clear OK to Lucentis as an option for treating visual impairment caused by diabetic macular edema after Novartis provided a bigger price discount and updated analyses showing the drug's superior relative effect among a sub-group of people with the condition.
AbbVie CEO Emphasizes Humira Growth Plans, Potential Of HCV Program AbbVie should appeal to long-term investors due to its sustainable business base and plan to issue and increase dividends over time, says CEO Richard Gonzalez.
First Non-Hormonal Hot Flash Drugs Could Clear FDA Panel In March Depomed's gabapentin and Noven Pharmaceuticals' paroxetine to get advisory committee review for a menopausal hot flash indication; while Phase III data for both drugs are positive, certain endpoints did not reach statistical significance in at least one study.
Merck's Frazier Optimistic About Pipeline Future Merck's Ken Frazier spoke about his faith in anaceptrapib, despite the recent failure of Tredaptive, at the recent Goldman Sachs Conference. He also addressed Merck's pipeline and consolidation in the industry.
GSK's COPD Drug Gets A New Name (Breo) But May Face Familiar Challenges At FDA Panel The respiratory drug's fate is uncertain given its mixed Phase III trial results; in two pivotal studies Breo, formerly Relovair, failed to demonstrate superiority to GSK's Advair.
Guerbet Looks To Separate Dotarem In Crowded Contrast Agent Market FDA advisory committee scheduled for Valentine's Day is key test for Guerbet's efforts to get its MRI imaging agent a wider indication than Bayer's Gadavist.
“The Pink Sheet” DAILY - daily in-depth analysis of the key developments shaping the biopharma industry. For more information call 1-800-332-2181. To register for a free trial, click here – no credit card needed.